KURA:NASDAQKura Oncology, Inc. Analysis

Kura Oncology (KURA) is trading at $9.36, comfortably above its 20‑day SMA of 10.70 and 50‑day SMA of 10.21, indicating a short‑term bullish bias, while the 200‑day SMA of 9.65 supports a longer‑term uptrend. RSI at 37.7 suggests modest downside momentum, and a bearish MACD histogram reinforces a near‑term pullback risk, compounded by a decreasing volume trend. The stock exhibits a high 30‑day volatility of 56% and a computed beta of 1.45, reflecting sensitivity to market swings, and the Fear & Greed Index is at an extreme‑greed 91.16, hinting at possible over‑optimism. On the fundamentals side, revenue surged 29.5% to $71.6 M, yet the company posts a widening loss (trailing EPS –$3.50) with negative gross (‑2.6%) and operating (‑4.3%) margins and a hefty EBITDA deficit of $‑316.6 M. Despite the loss, KURA holds a strong cash buffer of $580.8 M against modest debt of $24.3 M, providing runway for its clinical programs. Analysts collectively rate the stock as a strong buy with a median price target of $28, implying a potential upside of over 230%, while upcoming long‑term follow‑up data on Darlifarnib at KCRS 2026 could serve as a catalyst.